- Bedoelde u
- pathogenicity
Zoekresultaten - 66 results
Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
Publication Type: Peer reviewed scientific article Authors: Ingrao, Fiona; Ngabirano, Eva; Rauw, Fabienne; Dauphin, Gwenaëlle; Bénédicte Lambrecht * Source: Vaccine (2024) Abstract: The application of recombinant herpesvirus of turkey, expressing the H9 h ...
Silver nanoparticle induced immunogenic cell death can improve immunotherapy
Publication Type: Peer reviewed scientific article Authors: Sargsian, Ara; Koutsoumpou, Xanthippi; Girmatsion, Hermon; Egil, Çan; Buttiens, Kiana; Luci, Carla Rios; Soenen, Stefaan J.; Manshian, Bella B. Source: Journal of Nanobiotechnology, Volume 22, Is ...
Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial.
immunogenicity of the most common travellers’ vaccine hepatitis A (HepA) and the pneumococcal conjugate vaccine (PCV) increasingly used both at home and before travel. METHODS: Volunteers aged ≥18 years (n = 305) ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
comparable antibody responses to the full dose in people <55 years. Here, we report the safety and immunogenicity of a fractional dose regimen of the BNT162 b2 vaccine. REDU- VAC is a participant-blinded, ...
Immunogenicity and one-year boostability of a 3-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-Centre clinical trial.
immunogenic, with all patients seroconverting at some point in the study. Although boostability 7 days after PEP was not 100%, nobody would wrongly be denied RIG when only administered to those who responded ...
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.
factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162 b2 vaccine. RESULTS: C-reactive protein (general marker of inflammation), interleukin (IL)-15 (a pro-inflammatory ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial (poster)
Publication Type: Scientific poster, presentation or proceeding Authors: Pieter Pannus; Stéphanie Depickère; Delphine Kemlin; Sarah Houben; Christophe Y. Neven; Leo Hendrickx; Johan Michiels; Willems, Elisabeth; Stéphane De Craeye; Antoine Francotte; Féli ...
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
Viral Biomarkers BNT162 Vaccine COVID-19 Vaccines Humans Immunity, Humoral Immunization Schedule Immunization, Secondary Immunogenicity, Vaccine Neoplasms Prospective Studies Risk Factors Time Factors ...
The Expression of Hemagglutinin by a Recombinant Newcastle Disease Virus Causes Structural Changes and Alters Innate Immune Sensing.
NDV-vectored vaccines expressing the immunogenic H5 hemagglutinin (rNDV- H5) are considered attractive candidates to protect poultry from both highly pathogenic avian influenza (HPAI) and Newcastle disease (ND). ...
Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide.
demonstrated that a confined N-terminal region of the FP is strongly immunogenic across diverse coronaviruses. Peptide-purified human antibodies targeting this conserved FP epitope exhibited broad binding of ...